

Clinuvel Pharmaceuticals Ltd (CUV) - Financial and Strategic SWOT Analysis Review

https://marketpublishers.com/r/CC5DE4C9B7DEN.html

Date: September 2021 Pages: 54 Price: US\$ 125.00 (Single User License) ID: CC5DE4C9B7DEN

Abstracts

Clinuvel Pharmaceuticals Ltd (CUV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.



Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Clinuvel Pharmaceuticals Ltd (Clinuvel Pharmaceuticals) is a biopharmaceutical company which focuses on the development of drugs for the treatment of light related severe skin disorders. The company's lead product candidate, Scenesse (afamelanotide) is a first-in-class drug targeting erythropoietic protoporphyria (EPP) and is approved in Europe, Australia and the US for treating adult EPP patients. Its other products under development includes CUV9900 and VLRX001 among others. Clinuvel Pharmaceuticals also focused on developing a pediatric formulation of Scenesse for EPP and OTC products for general photoprotective application. The company through its subsidiaries has operations in Australia, Switzerland, Ireland, the UK, the US and Singapore. Clinuvel Pharmaceuticals is headquartered in Melbourne, Victoria, Australia.

Clinuvel Pharmaceuticals Ltd Key Recent Developments

Aug 26,2021: Clinuvel Delivers Record Revenues and Profit Aug 26,2021: Appendix 4E and Preliminary Financial Report Mar 10,2021: Investor Presentation - Daiwa Investment Conference Tokyo 2021 Feb 24,2021: Clinuvel reports tenth consecutive half year net profit Oct 29,2020: Clinuvel Pharmaceuticals: Appendix 4C and activity report



Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.



Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Contents

SECTION 1 - ABOUT THE COMPANY

Clinuvel Pharmaceuticals Ltd - Key Facts Clinuvel Pharmaceuticals Ltd - Key Employees Clinuvel Pharmaceuticals Ltd - Key Employee Biographies Clinuvel Pharmaceuticals Ltd - Major Products and Services Clinuvel Pharmaceuticals Ltd - History Clinuvel Pharmaceuticals Ltd - Company Statement Clinuvel Pharmaceuticals Ltd - Locations And Subsidiaries Head Office Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview Clinuvel Pharmaceuticals Ltd - Business Description Geographical Segment: European Economic Area and USA Performance Geographical Segment: Switzerland, Others Performance R&D Overview Clinuvel Pharmaceuticals Ltd - Corporate Strategy Clinuvel Pharmaceuticals Ltd - SWOT Analysis SWOT Analysis - Overview Clinuvel Pharmaceuticals Ltd - Strengths Clinuvel Pharmaceuticals Ltd - Strengths Clinuvel Pharmaceuticals Ltd - Weaknesses Clinuvel Pharmaceuticals Ltd - Opportunities Clinuvel Pharmaceuticals Ltd - Threats Clinuvel Pharmaceuticals Ltd - Threats

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios Financial Ratios - Annual Ratios Performance Chart Financial Performance Financial Ratios - Interim Ratios



Financial Ratios - Ratio Charts

SECTION 4 – COMPANY'S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Clinuvel Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021 Clinuvel Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021 Clinuvel Pharmaceuticals Ltd, Recent Deals Summary

SECTION 5 – COMPANY'S RECENT DEVELOPMENTS

Aug 26, 2021: Clinuvel Delivers Record Revenues and Profit
Aug 26, 2021: Appendix 4E and Preliminary Financial Report
Mar 10, 2021: Investor Presentation - Daiwa Investment Conference Tokyo 2021
Feb 24, 2021: Clinuvel reports tenth consecutive half year net profit
Oct 29, 2020: Clinuvel Pharmaceuticals: Appendix 4C and activity report
Aug 31, 2020: CLINUVEL opens VALLAURIX R&D Centre In Singapore
Aug 27, 2020: Clinuvel: Executive summary activity report quarter ending 31 March
2020
Mar 02, 2020: Supply of Scenesse unaffected by coronavirus
Feb 24, 2020: Clinuvel expands Singapore laboratories

SECTION 6 – APPENDIX

Methodology Ratio Definitions About GlobalData Contact Us Disclaimer



List Of Tables

LIST OF TABLES

Clinuvel Pharmaceuticals Ltd, Key Facts Clinuvel Pharmaceuticals Ltd, Key Employees Clinuvel Pharmaceuticals Ltd, Key Employee Biographies Clinuvel Pharmaceuticals Ltd, Major Products and Services Clinuvel Pharmaceuticals Ltd, History Clinuvel Pharmaceuticals Ltd, Other Locations Clinuvel Pharmaceuticals Ltd, Subsidiaries **Clinuvel Pharmaceuticals Ltd, Key Competitors** Clinuvel Pharmaceuticals Ltd, Ratios based on current share price Clinuvel Pharmaceuticals Ltd, Annual Ratios Clinuvel Pharmaceuticals Ltd, Annual Ratios (Cont...1) Clinuvel Pharmaceuticals Ltd, Annual Ratios (Cont...2) Clinuvel Pharmaceuticals Ltd, Interim Ratios Clinuvel Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021 Clinuvel Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021 Clinuvel Pharmaceuticals Ltd, Recent Deals Summary **Currency Codes Capital Market Ratios** Equity Ratios **Profitability Ratios** Cost Ratios Liquidity Ratios Leverage Ratios

Efficiency Ratios



List Of Figures

LIST OF FIGURES

Clinuvel Pharmaceuticals Ltd, Performance Chart (2017 - 2021) Clinuvel Pharmaceuticals Ltd, Ratio Charts Clinuvel Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021 Clinuvel Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021



I would like to order

Product name: Clinuvel Pharmaceuticals Ltd (CUV) - Financial and Strategic SWOT Analysis Review Product link: <u>https://marketpublishers.com/r/CC5DE4C9B7DEN.html</u>

Price: US\$ 125.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: <u>info@marketpublishers.com</u>

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/CC5DE4C9B7DEN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970